protocolSection identificationModule nctId: NCT06291259, orgStudyIdInfo id: CTO 4081, briefTitle: Mpox Prospective Observational Cohort Study, acronym: MPOCS, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-21, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Unity Health Toronto, class: OTHER, descriptionModule briefSummary: The goal of this multicentre prospective observational cohort study is to shed light on the following unknowns:1. The clinical manifestations of Mpox infection since the 2022 outbreak in Canada.2. The social and psychological impacts of Mpox infection since the 2022 outbreak in Canada3. The transmissibility of Mpox infection4. Viral shedding over time in infected individualsThe study is divided into Part 1 (corresponding to the acute phase of illness) and Part 2 (corresponding to the convalescent phase of the illness); part 2 will be optional. Participants enrolled during the acute phase of illness will complete part 1 of the study and will be invited to participate in Part 2 as well. Part 1 of the study will include the following three core components, at baseline and weekly (±3 days) until one week after the resolution of all symptoms (i.e. one week after complete healing of skin lesions):1. Collection of clinical data through chart review and research staff interviews with study participants2. Participant self-administered online questionnaires at baseline and a thrice-weekly 'acute phase participant diary'3. Specimen collection for Mpox-related testing Optional components for Part 1 include baseline-only, questionnaire-only, and frequent sampling.Other optional components for all participants include in the Image Atlas, an online database of clinical images of mpox, designed to provide clinicians and community members of what mpox looks like in real life, and the biobank, which will store research samples for potential future studies., conditionsModule conditions: Monkeypox, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Description of clinical manifestation, primaryOutcomes measure: Psychosocial impact, primaryOutcomes measure: Transmission-related aspects of mpox infection, primaryOutcomes measure: Virologic aspects of mpox infection over time, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: BC Centre For Excellence, status: RECRUITING, city: Vancouver, state: British Columbia, zip: V6Z 1Y6, country: Canada, contacts name: Brody Lyon, role: CONTACT, phone: 604-682-2344, phoneExt: 66230, email: blyons@bccfe.ca, contacts name: Mark Hull, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 49.24966, lon: -123.11934, locations facility: Unity Health Toronto, status: RECRUITING, city: Toronto, state: Ontario, zip: M5B 1T8, country: Canada, contacts name: Shreya Shah, role: CONTACT, phone: 416-360-4000, phoneExt: 77312, email: shreya.khera@unityhealth.to, contacts name: Darrell HS Tan, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, locations facility: University Health Network, status: RECRUITING, city: Toronto, state: Ontario, country: Canada, contacts name: Asmaa Mabrouk, role: CONTACT, phone: 416-340-4800, phoneExt: 2240, email: Asmaa.mabrouk@uhn.ca, contacts name: Sharon Walmsley, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False